Your browser doesn't support javascript.
loading
Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
Enache, Oana M; Rendo, Veronica; Abdusamad, Mai; Lam, Daniel; Davison, Desiree; Pal, Sangita; Currimjee, Naomi; Hess, Julian; Pantel, Sasha; Nag, Anwesha; Thorner, Aaron R; Doench, John G; Vazquez, Francisca; Beroukhim, Rameen; Golub, Todd R; Ben-David, Uri.
Afiliación
  • Enache OM; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Rendo V; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Abdusamad M; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Lam D; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Davison D; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Pal S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Currimjee N; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hess J; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Pantel S; Genetic Perturbation Platform, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Nag A; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Thorner AR; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Doench JG; Genetic Perturbation Platform, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Vazquez F; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Beroukhim R; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Golub TR; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ben-David U; Harvard Medical School, Boston, MA, USA.
Nat Genet ; 52(7): 662-668, 2020 07.
Article en En | MEDLINE | ID: mdl-32424350
Cas9 is commonly introduced into cell lines to enable CRISPR-Cas9-mediated genome editing. Here, we studied the genetic and transcriptional consequences of Cas9 expression itself. Gene expression profiling of 165 pairs of human cancer cell lines and their Cas9-expressing derivatives revealed upregulation of the p53 pathway upon introduction of Cas9, specifically in wild-type TP53 (TP53-WT) cell lines. This was confirmed at the messenger RNA and protein levels. Moreover, elevated levels of DNA repair were observed in Cas9-expressing cell lines. Genetic characterization of 42 cell line pairs showed that introduction of Cas9 can lead to the emergence and expansion of p53-inactivating mutations. This was confirmed by competition experiments in isogenic TP53-WT and TP53-null (TP53-/-) cell lines. Lastly, Cas9 was less active in TP53-WT than in TP53-mutant cell lines, and Cas9-induced p53 pathway activation affected cellular sensitivity to both genetic and chemical perturbations. These findings may have broad implications for the proper use of CRISPR-Cas9-mediated genome editing.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Proteína 9 Asociada a CRISPR / Mutación Límite: Humans Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Proteína 9 Asociada a CRISPR / Mutación Límite: Humans Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos